Mayer-Rokitansky-Küster-Hauser syndrome type 1

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:247775OMIM:277000Q51.8
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome type 1, also known as Rokitansky sequence or isolated Müllerian aplasia, is a congenital condition characterized by the absence or severe underdevelopment (agenesis or aplasia) of the uterus and the upper two-thirds of the vagina in individuals who are genetically female (46,XX karyotype). Type 1 is the isolated form of MRKH syndrome, meaning the Müllerian duct abnormalities occur without significant associated malformations of other organ systems, distinguishing it from the more complex type 2 form. Affected individuals have normally functioning ovaries, normal external genitalia, normal secondary sexual characteristics (breast development, pubic and axillary hair), and a typical female karyotype. The condition is most commonly diagnosed during adolescence when an individual presents with primary amenorrhea (absence of menstrual periods) despite otherwise normal pubertal development. Because the ovaries function normally, hormonal profiles are typically within the expected female range, and secondary sexual characteristics develop as expected. The lower portion of the vagina may be present as a shallow dimple or short pouch. Since the uterus is absent or rudimentary, natural pregnancy is not possible, though biological motherhood may be achieved through assisted reproductive technologies using the patient's own oocytes with gestational surrogacy, or more recently through uterine transplantation, which has resulted in successful pregnancies and live births in some centers. The primary treatment for MRKH syndrome type 1 focuses on the creation of a functional neovagina to allow for sexual intercourse. First-line treatment is typically non-surgical vaginal dilation therapy (Frank method), which uses graduated dilators to progressively lengthen the vaginal canal. When dilation therapy is unsuccessful, surgical vaginoplasty procedures such as the McIndoe technique, Vecchietti procedure, or Davydov procedure may be considered. Psychological support and counseling are important components of care, as the diagnosis can have significant emotional impact related to fertility, sexuality, and identity. Long-term outcomes with appropriate management are generally favorable, and affected individuals can lead full, healthy lives.

Also known as:

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Juvenile

Begins in the teen years

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Mayer-Rokitansky-Küster-Hauser syndrome type 1.

View clinical trials →

No actively recruiting trials found for Mayer-Rokitansky-Küster-Hauser syndrome type 1 at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Mayer-Rokitansky-Küster-Hauser syndrome type 1 community →

No specialists are currently listed for Mayer-Rokitansky-Küster-Hauser syndrome type 1.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Mayer-Rokitansky-Küster-Hauser syndrome type 1.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Mayer-Rokitansky-Küster-Hauser syndrome type 1Forum →

No community posts yet. Be the first to share your experience with Mayer-Rokitansky-Küster-Hauser syndrome type 1.

Start the conversation →

Latest news about Mayer-Rokitansky-Küster-Hauser syndrome type 1

No recent news articles for Mayer-Rokitansky-Küster-Hauser syndrome type 1.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Mayer-Rokitansky-Küster-Hauser syndrome type 1

What is Mayer-Rokitansky-Küster-Hauser syndrome type 1?

Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome type 1, also known as Rokitansky sequence or isolated Müllerian aplasia, is a congenital condition characterized by the absence or severe underdevelopment (agenesis or aplasia) of the uterus and the upper two-thirds of the vagina in individuals who are genetically female (46,XX karyotype). Type 1 is the isolated form of MRKH syndrome, meaning the Müllerian duct abnormalities occur without significant associated malformations of other organ systems, distinguishing it from the more complex type 2 form. Affected individuals have normally functioning

At what age does Mayer-Rokitansky-Küster-Hauser syndrome type 1 typically begin?

Typical onset of Mayer-Rokitansky-Küster-Hauser syndrome type 1 is juvenile. Age of onset can vary across affected individuals.